What is HC Wainwright’s Forecast for FHTX FY2026 Earnings?

Foghorn Therapeutics Inc. (NASDAQ:FHTX) – Stock analysts at HC Wainwright increased their FY2026 earnings per share estimates for Foghorn Therapeutics in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of $0.09 for the year, up from their previous forecast of ($0.91). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Foghorn Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Foghorn Therapeutics’ Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.36) EPS, Q2 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.37) EPS, Q4 2027 earnings at ($0.39) EPS, FY2027 earnings at ($1.47) EPS, FY2028 earnings at ($1.46) EPS, FY2029 earnings at ($1.44) EPS and FY2030 earnings at ($1.43) EPS.

Foghorn Therapeutics (NASDAQ:FHTX) last released its earnings results on Monday, November 9th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of ($0.24) by $1.04. The firm had revenue of $83.54 million during the quarter, compared to analyst estimates of $7.10 million. Foghorn Therapeutics had a negative return on equity of 13.46% and a net margin of 8.40%.

FHTX has been the subject of a number of other research reports. TD Cowen downgraded shares of Foghorn Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 1st. Evercore lowered shares of Foghorn Therapeutics from an “outperform” rating to an “in-line” rating and set a $3.00 price objective on the stock. in a report on Tuesday, October 13th. Wedbush cut shares of Foghorn Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $10.00 to $2.00 in a research report on Friday, October 2nd. BTIG Research downgraded shares of Foghorn Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, October 1st. Finally, Wall Street Zen upgraded shares of Foghorn Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Foghorn Therapeutics has an average rating of “Hold” and an average price target of $6.14.

Foghorn Therapeutics Trading Up 10.0%

Shares of NASDAQ:FHTX opened at $2.09 on Thursday. The stock’s 50-day moving average price is $2.90 and its two-hundred day moving average price is $4.56. Foghorn Therapeutics has a 12-month low of $1.79 and a 12-month high of $7.61. The firm has a market cap of $124.11 million, a price-to-earnings ratio of 29.86 and a beta of 3.22.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in FHTX. Canada Pension Plan Investment Board acquired a new position in Foghorn Therapeutics in the second quarter valued at $122,000. Bank of America Corp DE acquired a new stake in Foghorn Therapeutics during the second quarter worth about $127,000. Squarepoint Ops LLC increased its stake in Foghorn Therapeutics by 25.6% during the second quarter. Squarepoint Ops LLC now owns 130,346 shares of the company’s stock worth $636,000 after acquiring an additional 26,603 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Foghorn Therapeutics in the 2nd quarter worth about $144,000. Finally, Deutsche Bank AG purchased a new position in shares of Foghorn Therapeutics in the 2nd quarter worth about $178,000. 61.55% of the stock is owned by hedge funds and other institutional investors.

Foghorn Therapeutics News Summary

Investors following FHTX have been watching these news items:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $5 price target, and raised its FY2026 EPS forecast from a loss of $0.91 to earnings of $0.09. That revision is a positive near-term signal, though it contrasts with the firm’s weaker later-year projections. HC Wainwright estimates and rating
• Negative Sentiment: HC Wainwright cut its FY2027–FY2030 EPS estimates substantially, from prior loss forecasts of roughly $0.65–$0.67 per share to losses of about $1.43–$1.47. It also lowered its Q4 2026 estimate to a $0.34-per-share loss from a $0.23 loss. The revisions point to a more difficult earnings outlook and may weigh on sentiment. HC Wainwright earnings estimates
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Foghorn investors. The announcement does not establish wrongdoing, but the investigation could add uncertainty and legal risk for shareholders. Pomerantz investor investigation announcement

About Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for cancer. Its research centers on chromatin regulatory systems, which help control how genes are expressed and can contribute to disease when disrupted. The company’s Gene Traffic Control platform is designed to identify drug targets within these systems. Foghorn has developed investigational programs targeting chromatin regulators, including components of the BAF complex; its candidates remain in development and are not approved medicines.